This finding has enormous potential to be tested in a clinical trial in the near future and developed into a novel treatment to overcome
therapeutic resistance of glioblastoma.»
Taken together, these observation impinge on one central problem: the development of rational targeting strategies aimed at
overcoming therapeutic resistance require the precise elucidation of the molecular mechanisms whereby carcinoma cells that undergo EMT acquire the functional traits that render them resistant to conventional therapy.
This approach is routinely utilized at USAMRIID to study the development of
viral therapeutic resistance against antiviral countermeasures, according to Dr. Gustavo Palacios, director of the center and senior author of the study.
This rate will be important for predictive models of
therapeutic resistance.